Gosta Labs, a healthtech company based in Helsinki, has garnered significant attention by raising €7.5 million in seed funding to enhance its AI operating system specifically for oncology. This financing endeavor underscores the urgency and demand for technologically advanced solutions in the medical field, particularly in the ever-evolving landscape of cancer care. With growing numbers of cancer cases and the complexity of treatment options, the need for efficient and effective healthcare solutions becomes more critical.
The healthtech industry has seen various innovative attempts to address complex medical challenges, including previous endeavors by Gosta Labs’ founders, who had successfully developed Kaiku Health. Their past product focused on patient-reported outcomes and was eventually acquired by Elekta in 2020. This acquisition marked a significant step in expanding digital health applications globally and now provides a strong foundation for Gosta Labs to build upon with their AI initiatives.
How Does Gosta Labs’ AI Operating System Work?
Gosta Labs’ innovative oncology-focused AI operating system processes complex data into structured, real-time outputs, offering significant utility to clinicians. It aims to systematize each patient visit by synthesizing and displaying patient journeys, thereby assisting healthcare professionals with automated clinical documentation. The AI also converts unstructured clinical data into meaningful insights, streamlining administrative tasks. This technological approach helps in both improving documentation efficiency and in providing actionable data during treatment.
What Are the Implications for Cancer Care?
The implications for cancer care are substantial as the AI system promises a reduction in the clinical workload, thereby freeing up more time for patient interaction and care. With projections indicating a sharp rise in cancer cases by 2050, the system aims to relieve some of the pressure off multidisciplinary teams faced with rapid decision-making in complex therapeutic scenarios. The AI enhances care quality by assessing pivotal clinical parameters and aligning decision-making processes with international standards, ensuring coherence and speed in patient care delivery.
At the 2025 ESMO Congress, the first real-world evaluations of the Gosta AI Operating System were unveiled, showing the system’s proficiency in producing structured consultation notes swiftly, respecting institutional norms. Its abilities to instantly assess Performance Status and CTCAE toxicity grades are crucial advancements. Notably, oncologists experienced a vast reduction in documentation time, enabling them to allocate more resources and time towards patient care.
Gosta Labs is keen to use the freshly acquired funds to propagate its AI assistant to oncology teams worldwide.
“We are striving to reduce the administrative burden on oncologists, enabling them to concentrate on patient care,”
stated the company. Another goal is to bolster the AI foundation of their medical-device-grade product, thereby enhancing safety and personalization in patient encounters.
The company’s foundation in 2023 by Lauri Sippola and Henri Viertolahti, within a team that amalgamates AI expertise with seasoned oncology leadership, indicates a strategic positioning in scaling cancer technologies.
“With a global perspective and a keen focus on digital solutions, our mission is clear,”
emphasized the co-founders, illustrating their commitment to integrating AI in enhancing healthcare outcomes. This focus has potential impacts on improving healthcare delivery worldwide.
